Neurocrine Bio. (NBIX) PT Raised to $163 at Morgan Stanley
Tweet
Share
E-mailGet Alerts NBIX Hot Sheet
Price: $165.11 +6.63%
Rating Summary:
30 Buy, 6 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 7 | Down: 20 | New: 25
Rating Summary:
30 Buy, 6 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 7 | Down: 20 | New: 25
Join SI Premium – FREE
Morgan Stanley analyst Jeffrey Hung raised the price target on Neurocrine Bio. (NASDAQ: NBIX) to $163.00 (from $158.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Goldman Sachs Upgrades Plains GP Holdings, L.P (PAGP) to Neutral
- Shiseido Co Ltd. (4911:JP) (SSDOY) PT Lowered to JPY2,750 at Nomura/Instinet
- Neurocrine Biosciences to Present New Two‑Year CRENESSITY® (crinecerfont) Data on Key Clinical and Patient‑Reported Outcome Measures at ENDO 2026
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
